The U.S. Food and Drug Administration today approved Nulojix (belatacept) to prevent acute rejection in adult patients who have had a kidney transplant. bwin The drug is approved for use with other immunosuppressants (medications that suppress the immune system) — specifically basiliximab, mycophenolate mofetil, and corticosteroids. العاب للربح من الانترنت